MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study

Reuters

2025/10/31

MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study

MediciNova Inc. announced the publication of a new research article in the Journal of Atherosclerosis and Thrombosis detailing the effects of tipelukast (MN-001) and its metabolite MN-002 on cholesterol metabolism. The study demonstrated that MN-002 significantly enhanced cholesterol efflux in macrophages by upregulating the transport proteins ABCA1 and ABCG1, suggesting a potential therapeutic strategy for atherosclerosis and other metabolic disorders. Previous clinical studies indicated that MN-001 improved serum lipid profiles in patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with notable effects in patients with type 2 diabetes. MediciNova is currently conducting a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD, with enrollment nearing completion. Results from this ongoing clinical trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565472-en) on October 30, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579104811"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579104811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579104811?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579104811","market":"fut","top_or_hot":-1,"title":"MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediciNova Inc. announced the publication of a new research article in the Journal of Atherosclerosis and Thrombosis detailing the effects of tipelukast (MN-001) and its metabolite MN-002 on cholesterol metabolism. The study demonstrated that MN-002 significantly enhanced cholesterol efflux in macrophages by upregulating the transport proteins ABCA1 and ABCG1, suggesting a potential therapeutic strategy for atherosclerosis and other metabolic disorders. Previous clinical studies indicated that MN-001 improved serum lipid profiles in patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with notable effects in patients with type 2 diabetes. MediciNova is currently conducting a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD, with enrollment nearing completion. Results from this ongoing clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565472-en) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediciNova Inc. announced the publication of a new research article in the Journal of Atherosclerosis and Thrombosis detailing the effects of tipelukast (MN-001) and its metabolite MN-002 on cholesterol metabolism. The study demonstrated that MN-002 significantly enhanced cholesterol efflux in macrophages by upregulating the transport proteins ABCA1 and ABCG1, suggesting a potential therapeutic strategy for atherosclerosis and other metabolic disorders. Previous clinical studies indicated that MN-001 improved serum lipid profiles in patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with notable effects in patients with type 2 diabetes. MediciNova is currently conducting a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD, with enrollment nearing completion. Results from this ongoing clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565472-en) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL23Bct0:1","article_id":"2579104811","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579104811","pubTimestamp":1761865216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire  on October 30, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","MNOV":"美第奇新星生物技术","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"MediciNova报告Tipelukast在胆固醇代谢研究中的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"MNOV":0.9},"content_text":"MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study\n    \n\n        MediciNova Inc. announced the publication of a new research article in the Journal of Atherosclerosis and Thrombosis detailing the effects of tipelukast (MN-001) and its metabolite MN-002 on cholesterol metabolism. The study demonstrated that MN-002 significantly enhanced cholesterol efflux in macrophages by upregulating the transport proteins ABCA1 and ABCG1, suggesting a potential therapeutic strategy for atherosclerosis and other metabolic disorders. Previous clinical studies indicated that MN-001 improved serum lipid profiles in patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with notable effects in patients with type 2 diabetes. MediciNova is currently conducting a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD, with enrollment nearing completion. Results from this ongoing clinical trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565472-en) on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}